It won't be long before Teva will make an acquisition in South America and Brazil looks like the top target. Sanofi is ahead of Teva there as it already bought the largest generics company - Medley. I think the Chinese market is probably still too fragmented to be a current top priority target for Teva, and they are waiting for regulatory changes to make a move.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.